Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacek Gronwald

Showing results (51-60 of 307) with videos related to

Pageof 31
Sort By:
Journal of Ovarian Research|March 2, 2016
Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancersJanusz Menkiszak, Anita Chudecka-Głaz, Jacek Gronwald, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapyTomasz Byrski, Jacek Gronwald, Tomasz Huzarski, et al.
Breast Cancer Research : BCR|July 24, 2012
Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancerTomasz Byrski, Rebecca Dent, Pawel Blecharz, et al.
Breast Cancer Research and Treatment|November 26, 2008
Synergistic interaction of variants in CHEK2 and BRCA2 on breast cancer riskPablo Serrano-Fernández, Tadeusz Debniak, Bohdan Górski, et al.
Journal of Applied Genetics|May 8, 2004
Ovarian cystadenoma as a characteristic feature of families with hereditary ovarian cancers unassociated with BRCA1 and BRCA2 mutationsJanusz Menkiszak, Marek Brzosko, Bohdan Górski, et al.
Breast Cancer Research and Treatment|December 17, 2017
Predictors of survival for breast cancer patients with a BRCA1 mutationSteven A Narod, Tomasz Huzarski, Jacek Gronwald, et al.
Breast Cancer Research and Treatment|August 10, 2006
A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in PolandCezary Cybulski, Dominika Wokołorczyk, Tomasz Huzarski, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 21, 2007
Epistatic relationship between the cancer susceptibility genes CHEK2 and p27Cezary Cybulski, Bartłomiej Gliniewicz, Andrzej Sikorski, et al.
Nutrients|May 11, 2024
Blood Cadmium Level Is a Marker of Cancer Risk in MenRóża Derkacz, Wojciech Marciniak, Piotr Baszuk, et al.
NPJ Breast Cancer|June 15, 2026
PCSK9 rs562556 variant and survival in BRCA1 mutation carriers and mutation-negative familial breast cancerCezary Cybulski, Wojciech Kluźniak, Dominika Wokołorczyk, et al.
Pageof 31

Showing results (51-60 of 307) with videos related to

Sort By:
Pageof 31
Journal of Ovarian Research|March 2, 2016
Prophylactic salpingo-oophorectomy in BRCA1 mutation carriers and postoperative incidence of peritoneal and breast cancersJanusz Menkiszak, Anita Chudecka-Głaz, Jacek Gronwald, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapyTomasz Byrski, Jacek Gronwald, Tomasz Huzarski, et al.
Breast Cancer Research : BCR|July 24, 2012
Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancerTomasz Byrski, Rebecca Dent, Pawel Blecharz, et al.
Breast Cancer Research and Treatment|November 26, 2008
Synergistic interaction of variants in CHEK2 and BRCA2 on breast cancer riskPablo Serrano-Fernández, Tadeusz Debniak, Bohdan Górski, et al.
Journal of Applied Genetics|May 8, 2004
Ovarian cystadenoma as a characteristic feature of families with hereditary ovarian cancers unassociated with BRCA1 and BRCA2 mutationsJanusz Menkiszak, Marek Brzosko, Bohdan Górski, et al.
Breast Cancer Research and Treatment|December 17, 2017
Predictors of survival for breast cancer patients with a BRCA1 mutationSteven A Narod, Tomasz Huzarski, Jacek Gronwald, et al.
Breast Cancer Research and Treatment|August 10, 2006
A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in PolandCezary Cybulski, Dominika Wokołorczyk, Tomasz Huzarski, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 21, 2007
Epistatic relationship between the cancer susceptibility genes CHEK2 and p27Cezary Cybulski, Bartłomiej Gliniewicz, Andrzej Sikorski, et al.
Nutrients|May 11, 2024
Blood Cadmium Level Is a Marker of Cancer Risk in MenRóża Derkacz, Wojciech Marciniak, Piotr Baszuk, et al.
NPJ Breast Cancer|June 15, 2026
PCSK9 rs562556 variant and survival in BRCA1 mutation carriers and mutation-negative familial breast cancerCezary Cybulski, Wojciech Kluźniak, Dominika Wokołorczyk, et al.
Pageof 31